Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Lung Cancer (Amsterdam, Netherlands)|June 30, 2024
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLCMariano Provencio, Lucía Robado de Lope, Roberto Serna-Blasco, et al.
JTO Clinical and Research Reports|March 25, 2024
<i>RET</i> Fusion Testing in Patients With NSCLC: The RETING StudyEsther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 26, 2024
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECPAylen Vanessa Ospina, Sergio Bolufer Nadal, José Luis Campo-Cañaveral de la Cruz, et al.
Translational Lung Cancer Research|October 24, 2025
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statementAylen Vanessa Ospina-Serrano, Jose Luis González-Larriba, Ernest Nadal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING StudyEsther Conde, Susana Hernandez, Rebeca Martinez, et al.
The Lancet. Oncology|January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Enric Carcereny, Radj Gervais, et al.
Pageof 6